What's Happening?
Merck Animal Health has received conditional approval from the FDA for Exzolt Cattle-CA1, a new isoxazoline parasiticide designed to combat New World Screwworm (NWS) and cattle fever tick. This pour-on solution is the first novel ectoparasiticide introduced
for beef cattle in decades. The approval comes as a response to the growing threat of NWS, which poses significant economic risks to U.S. agriculture, potentially costing cattle producers hundreds of millions of dollars. The product is approved for use in beef cattle aged two months and older and replacement dairy heifers under 20 months, but not for bulls intended for breeding, dairy calves, or veal calves. The FDA's accelerated regulatory pathway facilitated the swift approval of this product, reflecting Merck's commitment to providing innovative solutions for parasite management.
Why It's Important?
The conditional approval of Exzolt Cattle-CA1 is significant for the U.S. cattle industry, as it addresses a critical need for effective parasite control. The introduction of this product could help prevent substantial economic losses by protecting cattle from NWS and cattle fever tick, which are known to cause severe health issues in livestock. By offering a new tool for parasite management, Merck supports the sustainability and economic viability of the cattle industry. This development also highlights the importance of regulatory pathways that enable the rapid introduction of essential veterinary products, ensuring that farmers and veterinarians have access to the latest innovations in animal health.
What's Next?
Merck plans to make Exzolt Cattle-CA1 available by prescription in early 2026, allowing veterinarians and cattle producers to incorporate it into their parasite management programs. The company will likely continue to work closely with the FDA to demonstrate the product's full effectiveness, aiming for full approval. As the product becomes available, stakeholders in the cattle industry will need to assess its impact on herd health and productivity. The success of Exzolt Cattle-CA1 could encourage further research and development in veterinary medicine, leading to more advanced solutions for livestock health challenges.
